rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Margaret McLoughlin

Director

Company insider

Files Form 4 as: Director, Quince Therapeutics.

In numbers

Trades disclosed
25
Buys
2
Sells
3
Bought
$19K
Sold
$692K
Companies
1
Companies where not an officer
1
First trade
8 May 2019
Last trade
2 Jan 2026
Last filed
21 Jan 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Quince TherapeuticsDirector · Biotechnology · last 2 Jan 20262 buys · 3 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
2 Jan 2026filed 21 Jan 2026Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,547 at $0.00filing
2 Jan 2026filed 21 Jan 2026Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,547 at $0.00filing
4 Jun 2025filed 6 Jun 2025Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—27,000 at $0.00filing
2 Jan 2025filed 8 Jan 2025Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—31,613 at $0.00filing
5 Jun 2024filed 7 Jun 2024Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—27,000 at $0.00filing
8 Aug 2023filed 9 Aug 2023Quince TherapeuticsBiotechnologySEC FORM 4 Bought$9,8408,000 at $1.23filing
24 May 2023filed 26 May 2023Quince Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—27,000 at $0.00filing
8 Jun 2022filed 9 Jun 2022IRLA IRulya Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—27,000 at $0.00filing
8 Oct 2021filed 12 Oct 2021IRLA IRulya Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—1,000 at $0.00filing
8 Oct 2021filed 12 Oct 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Code M$17K1,000 at $17.00filing
8 Oct 2021filed 12 Oct 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$89K1,000 at $88.93filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—6,000 at $0.00filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Code M$102K6,000 at $17.00filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$289K3,056 at $94.55filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$100K1,044 at $95.57filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$138K1,429 at $96.51filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$41K423 at $97.55filing
16 Aug 2021filed 18 Aug 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$4,74748 at $98.90filing
28 Jun 2021filed 29 Jun 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$11K200 at $55.01filing
28 Jun 2021filed 29 Jun 2021IRLA IRulya TherapeuticsBiotechnologySEC FORM 4 Sold$14K250 at $55.03filing

News

IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst ConferenceIRLA · manilatimes.net · 15 Oct 2026

0 headlines in the last 90 days name Margaret McLoughlin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care5

Buys in green, sells in red, by the company’s sector.

Related people

Christopher J. SennerDirector · Director at Quince Therapeutics, filing Form 4 there in the last year
David LamondDirector · Director at Quince Therapeutics, filing Form 4 there in the last year
Brigette RobertsChief Corp. Affairs Officer · Chief Corp. Affairs Officer at Quince Therapeutics, filing Form 4 there in the last year
Dirk ThyeCEO and CMO · CEO and CMO at Quince Therapeutics, filing Form 4 there in the last year
Charles S. RyanPresident · President at Quince Therapeutics, filing Form 4 there in the last year